Table 1 Clinical trials of selinexor and eltanexor in hematological malignancies
From: XPO1-dependent nuclear export as a target for cancer therapy
Diseases | Drug(s) | Study phase | No. of patients | Outcome (ORR) | NCT number |
|---|---|---|---|---|---|
RR AML | Selinexor | I | 95 | 14% | NCT01607892 |
RR AML | Selinexor/MEC | I | 21 | 39% | NCT02299518 |
AML | Selinexor/cytarabine/mitoxantrone | I | 20 | 70% | NCT02573363 |
FLT3-mutated AML | Selinexor/sorafenib | IB/II | 14 | 43% | NCT02530476 |
Pediatric RR leukemia | Selinexor/fludarabine/cytarabine | I | 18 | 47% | NCT02212561 |
RR NHL | Selinexor | I | 79 | 31% | NCT01607892 |
RR DLBCL | Selinexor | IIB | 129 | Ongoing | NCT02227251 |
RR DLBCL | Selinexor/RICE | I | 23 | Ongoing | NCT02471911 |
Advanced NHL | Selinexor/R-CHOP | IB/II | 44 | Ongoing | NCT03147885 |
RR CLL/NHL | Selinexor/ibrutinib | I | 92 | Ongoing | NCT02303392 |
DLBCL/AML | Selinexor/venetoclax | I | 78 | Ongoing | NCT03955783 |
RR MM | Selinexor/dexamethasone | I | 59 | 50% vs 4% | NCT01607892 |
RR MM | Selinexor/dexamethasone | IIB | 202 | 26% | NCT02336815 |
RR MM | Selinexor/dexamethasone/bortezomib | I/II | 42 | 63% | NCT02343042 |
RR MM | Selinexor/dexamethasone/bortezomib | III | 402 | 13.93 vs 9.46 months (PFS) | NCT03110562 |
RR MM/MDS | Eltanexor (KPT-8602) | I/II | 119 | Ongoing | NCT02649790 |